Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Peter J Barris. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Peter J Barris har rapporteret besiddelser eller handler i følgende virksomheder:
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Peter J Barris. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb APPN / Appian Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg APPN / Appian Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ARDX / Ardelyx, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ARDX / Ardelyx, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-12-26 | ARDX | BARRIS PETER J | 1.972 | 21,2784 | 1.972 | 21,2784 | 41.961 | 131 | 8.32 | -25.554 | -60,90 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AVTX / Avalo Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AVTX / Avalo Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BE / Bloom Energy Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-07-27 | BE | NEW ENTERPRISE ASSOCIATES 10 L P | 1.333.333 | 15,0000 | 1.333.333 | 15,0000 | 19.999.995 | 61 | 35.8 | 27.733.326 | 138,67 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BE / Bloom Energy Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BOX / Box, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BOX / Box, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CSBR / Champions Oncology, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CSBR / Champions Oncology, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb DERM / Journey Medical Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg DERM / Journey Medical Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb FOLD / Amicus Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2012-03-07 | FOLD | BARRIS PETER J | 214.846 | 5,7000 | 214.846 | 5,7000 | 1.224.622 | 133 | 6.51 | 174.025 | 14,21 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg FOLD / Amicus Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GNCAQ / Genocea Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GNCAQ / Genocea Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GRPN / Groupon, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GRPN / Groupon, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GRTX / Galera Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-11-12 | GRTX | New Enterprise Associates 14, L.P. | 416.666 | 12,0000 | 416.666 | 12,0000 | 4.999.992 | 111 | 17.67 | 2.362.496 | 47,25 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GRTX / Galera Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MIRM / Mirum Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MIRM / Mirum Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MRKR / Marker Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MRKR / Marker Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MRSN / Mersana Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-03-05 | MRSN | New Enterprise Associates 14, L.P. | 3.750.000 | 4,0000 | 150.000 | 100,0000 | 15.000.000 | 358 | 9.2800 | -13.608.000 | -90,72 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MRSN / Mersana Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NITE / Capitol Series Trust - The Nightview Fund – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NITE / Capitol Series Trust - The Nightview Fund – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NN / NextNav Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NN / NextNav Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SENS / Senseonics Holdings, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SENS / Senseonics Holdings, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SPT / Sprout Social, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SPT / Sprout Social, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SUPN / Supernus Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2012-05-04 | SUPN | NEW ENTERPRISE ASSOCIATES 11 LP | 4.400.000 | 5,0000 | 4.400.000 | 5,0000 | 22.000.000 | 76 | 14.86 | 43.384.000 | 197,20 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SUPN / Supernus Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SYBX / Synlogic, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SYBX / Synlogic, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TPST / Tempest Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TPST / Tempest Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TRVI / Trevi Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TRVI / Trevi Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TRVN / Trevena, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TRVN / Trevena, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VG / Venture Global, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VG / Venture Global, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Peter J Barris som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-23 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
A - Award | 8.298 | 30.783 | 36,90 | ||||
2025-05-22 |
|
4 | TEM |
Tempus AI, Inc.
Class A Comnmon Stock |
A - Award | 1.997 | 115.511 | 1,76 | ||||
2024-06-17 |
|
4 | TEM |
Tempus AI, Inc.
Class A Comnmon Stock |
C - Conversion | 100.000 | 113.514 | 739,97 | ||||
2024-06-17 |
|
4 | TEM |
Tempus AI, Inc.
Non-Voting Common Stock |
C - Conversion | -100.000 | 0 | -100,00 | ||||
2024-06-17 |
|
4 | TEM |
Tempus AI, Inc.
Class A Common Stock |
A - Award | 13.514 | 13.514 | |||||
2024-06-13 | 3 | TEM |
Tempus AI, Inc.
Non-Voting Common Stock |
100.000 | ||||||||
2024-05-23 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
A - Award | 5.612 | 22.485 | 33,26 | ||||
2023-07-24 |
|
4 | BGRY |
Berkshire Grey, Inc.
Class A Common Stock |
D - Sale to Issuer | -156.713 | 0 | -100,00 | ||||
2023-05-24 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
A - Award | 3.895 | 16.873 | 30,01 | ||||
2022-12-15 |
|
4 | ZFOX |
ZeroFox Holdings, Inc.
Common Stock |
A - Award | 42.918 | 42.918 | |||||
2022-08-05 | 3 | ZFOX |
ZeroFox Holdings, Inc.
Common Stock |
0 | ||||||||
2022-06-27 |
|
4/A | BGRY |
Berkshire Grey, Inc.
Class A Common Stock |
A - Award | 91.667 | 156.713 | 140,93 | ||||
2022-06-24 |
|
4 | BGRY |
Berkshire Grey, Inc.
Class A Common Stock |
A - Award | 91.667 | 156.713 | 140,93 | ||||
2022-06-23 |
|
4 | NN |
NEXTNAV INC.
Common Stock |
A - Award | 41.170 | 57.282 | 255,52 | ||||
2022-06-17 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
A - Award | 12.497 | 24.614 | 103,14 | ||||
2022-05-27 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
A - Award | 4.164 | 12.978 | 47,24 | ||||
2022-04-25 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 1.046 | 13.608 | 8,33 | ||||
2022-02-04 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 863 | 12.562 | 7,38 | ||||
2021-12-29 |
|
4 | NN |
NEXTNAV INC.
Common Stock |
A - Award | 16.112 | 16.112 | |||||
2021-10-18 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 867 | 11.699 | 8,00 | ||||
2021-09-29 |
|
4 | BGRY |
Berkshire Grey, Inc.
Class A Common Stock |
A - Award | 43.364 | 65.046 | 200,00 | ||||
2021-09-29 |
|
4 | BGRY |
Berkshire Grey, Inc.
Class A Common Stock |
A - Award | 21.682 | 21.682 | |||||
2021-07-19 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 513 | 10.832 | 4,97 | ||||
2021-06-17 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
A - Award | 4.346 | 12.117 | 55,93 | ||||
2021-05-28 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
A - Award | 2.394 | 8.814 | 37,29 | ||||
2021-05-20 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | 13.701 | 49.623 | 38,14 | ||||
2021-05-20 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | 13.701 | 49.623 | 38,14 | ||||
2021-04-26 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 453 | 10.319 | 4,59 | ||||
2021-02-25 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | 13.701 | 35.922 | 61,66 | ||||
2021-02-25 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | 13.701 | 35.922 | 61,66 | ||||
2021-01-29 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 660 | 9.877 | 7,16 | ||||
2021-01-04 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 1.701 | 9.217 | 22,63 | ||||
2021-01-04 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
A - Award | 5.229 | 7.771 | 205,70 | ||||
2020-11-17 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | 22.221 | 22.221 | |||||
2020-11-17 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | 22.221 | 22.221 | |||||
2020-05-29 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
A - Award | 6.420 | 6.420 | |||||
2020-02-07 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 6.523 | 150.330 | 4,54 | ||||
2019-12-26 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Class A-2 Convertible Preferred Stock |
P - Purchase | 900.900 | 900.900 | 6,66 | 5.999.994 | 5.999.994 | ||
2019-12-26 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Common Stock Purchase Warrant (Right to Buy) |
P - Purchase | 9.009.000 | 9.009.000 | 0,12 | 1.126.125 | 1.126.125 | ||
2019-12-26 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
S - Sale | X | -210.124 | 50.858 | -80,51 | 2,34 | -490.955 | 118.830 |
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -268.679 | 0 | -100,00 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -832.126 | 0 | -100,00 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -1.837.275 | 0 | -100,00 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -6.086.620 | 0 | -100,00 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
C - Conversion | 268.679 | 9.024.700 | 3,07 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
C - Conversion | 832.126 | 8.756.021 | 10,50 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
C - Conversion | 1.837.275 | 7.923.895 | 30,19 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
C - Conversion | 6.086.620 | 6.086.620 | |||||
2019-12-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
A - Award | 400.000 | 3.482.186 | 12,98 | 6,25 | 2.500.000 | 21.763.662 | |
2019-12-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
A - Award | 400.000 | 3.482.186 | 12,98 | 6,25 | 2.500.000 | 21.763.662 | |
2019-11-29 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -1.166.755 | 4.270.691 | -21,46 | 2,52 | -2.941.739 | 10.767.693 | |
2019-11-29 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -117.164 | 5.437.446 | -2,11 | 2,45 | -287.134 | 13.325.549 | |
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.354.829 | 0 | -100,00 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -9.600.000 | 0 | -100,00 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -8.975.000 | 0 | -100,00 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Common Stock |
P - Purchase | 416.666 | 4.358.047 | 10,57 | 12,00 | 4.999.992 | 52.296.564 | |
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Common Stock |
C - Conversion | 267.935 | 3.941.381 | 7,29 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Common Stock |
C - Conversion | 1.898.524 | 3.673.446 | 106,96 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Common Stock |
C - Conversion | 1.774.922 | 1.774.922 | |||||
2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.061.547 | 0 | -100,00 | ||||
2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3.606.282 | 0 | -100,00 | ||||
2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 935.000 | 5.925.287 | 18,74 | 16,00 | 14.960.000 | 94.804.592 | |
2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 1.061.547 | 4.990.287 | 27,02 | ||||
2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 3.606.282 | 3.928.740 | 1.118,37 | ||||
2019-10-31 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
644.916 | ||||||||
2019-10-31 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
644.916 | ||||||||
2019-10-31 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
644.916 | ||||||||
2019-10-21 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 6.782 | 143.807 | 4,95 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Class B Common Stock |
C - Conversion | 42.463.920 | 48.588.474 | 693,34 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -4.059.376 | 0 | -100,00 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -7.183.310 | 0 | -100,00 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -35.280.610 | 0 | -100,00 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
C - Conversion | 4.059.376 | 4.059.376 | |||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -29.889.945 | 0 | -100,00 | ||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 450.000 | 4.186.243 | 12,04 | 15,00 | 6.750.000 | 62.793.645 | |
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 3.736.243 | 3.736.243 | |||||
2019-07-19 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 5.987 | 137.025 | 4,57 | ||||
2019-06-25 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
P - Purchase | 2.857.142 | 7.225.676 | 65,40 | 3,50 | 9.999.997 | 25.289.866 | |
2019-06-17 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
A - Award | 51.316 | 260.982 | 24,48 | ||||
2019-06-07 |
|
4 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
D - Sale to Issuer | -6.662.532 | 0 | -100,00 | 25,50 | -169.894.566 | ||
2019-05-13 |
|
4 | TRVI |
Trevi Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -17.099.315 | 0 | -100,00 | ||||
2019-05-13 |
|
4 | TRVI |
Trevi Therapeutics, Inc.
Common Stock |
P - Purchase | 1.500.000 | 4.438.562 | 51,05 | 10,00 | 15.000.000 | 44.385.620 | |
2019-05-13 |
|
4 | TRVI |
Trevi Therapeutics, Inc.
Common Stock |
P - Purchase | 1.000.000 | 2.938.562 | 51,58 | 10,00 | 10.000.000 | 29.385.620 | |
2019-05-13 |
|
4 | TRVI |
Trevi Therapeutics, Inc.
Common Stock |
C - Conversion | 1.938.562 | 1.938.562 | |||||
2019-05-09 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Class A-1 Convertible Preferred Stock |
P - Purchase | 256.700 | 256.700 | 10,80 | 2.772.360 | 2.772.360 | ||
2019-05-09 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Common Stock Purchase Warrant (Right to Buy) |
P - Purchase | 3.703.704 | 3.703.704 | 0,12 | 462.963 | 462.963 | ||
2019-05-09 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
P - Purchase | 1.136.704 | 2.052.454 | 124,13 | 1,08 | 1.227.640 | 2.216.650 | |
2019-04-22 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 5.850 | 131.038 | 4,67 | ||||
2019-04-08 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Warrant to Purchase Common Stock |
P - Purchase | 4.347.827 | 4.347.827 | 0,01 | 43.478 | 43.478 | ||
2019-04-08 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.347.827 | 25.243.865 | 20,81 | 1,14 | 4.956.523 | 28.778.006 | |
2019-03-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
P - Purchase | 3.750.000 | 11.890.138 | 46,07 | 4,00 | 15.000.000 | 47.560.552 | |
2019-02-19 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Warrant to Purchase Common Stock |
P - Purchase | 2.487.067 | 2.487.067 | 0,12 | 310.883 | 310.883 | ||
2019-02-19 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
P - Purchase | 9.948.269 | 34.948.269 | 39,79 | 0,47 | 4.688.619 | 16.471.119 | |
2019-02-08 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 5.503 | 125.188 | 4,60 | ||||
2019-01-22 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
U - Other | -767 | 0 | -100,00 | 75,00 | -57.525 | ||
2019-01-22 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
U - Other | -767 | 0 | -100,00 | 75,00 | -57.525 | ||
2019-01-22 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
U - Other | -739.517 | 0 | -100,00 | 75,00 | -55.463.775 | ||
2019-01-22 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
U - Other | -9.681.038 | 0 | -100,00 | 75,00 | -726.077.850 | ||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2019-01-02 | 3 | NITE |
Nightstar Therapeutics plc
Ordinary Shares |
13.325.064 | ||||||||
2018-12-21 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 300.000 | 20.896.038 | 1,46 | 1,49 | 448.380 | 31.231.218 | |
2018-12-21 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 200.000 | 20.596.038 | 0,98 | 1,63 | 326.060 | 33.577.721 | |
2018-12-14 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 645.161 | 6.135.234 | 11,75 | 15,50 | 9.999.996 | 95.096.127 | |
2018-12-12 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 61.200 | 20.396.038 | 0,30 | 1,98 | 121.084 | 40.353.561 | |
2018-12-11 | 3 | MLND |
Millendo Therapeutics, Inc.
Common Stock |
3.532.814 | ||||||||
2018-12-11 | 3 | MLND |
Millendo Therapeutics, Inc.
Common Stock |
3.532.814 | ||||||||
2018-12-11 | 3 | MLND |
Millendo Therapeutics, Inc.
Common Stock |
3.532.814 | ||||||||
2018-12-10 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 26.000 | 20.334.838 | 0,13 | 1,98 | 51.576 | 40.338.218 | |
2018-12-10 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 117.100 | 20.308.838 | 0,58 | 1,98 | 232.362 | 40.298.827 | |
2018-12-10 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 27.300 | 20.191.738 | 0,14 | 1,99 | 54.414 | 40.246.172 | |
2018-11-30 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 71.900 | 20.164.438 | 0,36 | 1,98 | 142.067 | 39.842.913 | |
2018-11-30 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 24.500 | 20.092.538 | 0,12 | 1,99 | 48.824 | 40.040.410 | |
2018-11-21 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 170.000 | 20.068.038 | 0,85 | 1,98 | 336.107 | 39.676.518 | |
2018-11-19 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 510.000 | 19.898.038 | 2,63 | 1,88 | 956.658 | 37.324.740 | |
2018-11-19 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 350.000 | 19.388.038 | 1,84 | 1,86 | 649.355 | 35.970.627 | |
2018-11-19 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 340.000 | 19.038.038 | 1,82 | 1,86 | 631.958 | 35.386.001 | |
2018-10-30 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 6.455 | 119.685 | 5,70 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | -1.124.301 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -437.706 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | -4.349 | 437.706 | -0,98 | 5,00 | -21.745 | 2.188.530 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
X - Other | 181.190 | 442.055 | 69,46 | 0,12 | 21.743 | 53.047 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
X - Other | -181.190 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -3.279.627 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
S - Sale | -1.177 | 3.279.627 | -0,04 | 5,00 | -5.885 | 16.398.135 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
X - Other | 49.030 | 3.280.804 | 1,52 | 0,12 | 5.884 | 393.696 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock |
X - Other | -49.030 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 1.800.000 | 6.641.634 | 37,18 | 5,00 | 9.000.000 | 33.208.170 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 4.841.634 | 4.841.634 | |||||
2018-10-18 | 3 | MRKR |
Marker Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-10-18 | 3 | MRKR |
Marker Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-10-18 | 3 | MRKR |
Marker Therapeutics, Inc.
Common Stock |
10.000.000 | ||||||||
2018-10-10 |
|
4 | ESTC |
Elastic N.V.
Series D Convertible Preference Shares |
C - Conversion | -1.528.117 | 0 | -100,00 | ||||
2018-10-10 |
|
4 | ESTC |
Elastic N.V.
Series C Convertible Preference Shares |
C - Conversion | -4.155.995 | 0 | -100,00 | ||||
2018-10-10 |
|
4 | ESTC |
Elastic N.V.
Ordinary Shares |
C - Conversion | 1.528.117 | 1.528.117 | |||||
2018-10-10 |
|
4 | ESTC |
Elastic N.V.
Ordinary Shares |
C - Conversion | 4.155.995 | 4.155.995 | |||||
2018-10-04 | 3 | ESTC |
Elastic N.V.
Ordinary Shares |
1.324.908 | ||||||||
2018-10-04 | 3 | ESTC |
Elastic N.V.
Ordinary Shares |
683.250 | ||||||||
2018-10-04 | 3 | ESTC |
Elastic N.V.
Ordinary Shares |
1.324.908 | ||||||||
2018-10-04 | 3 | ESTC |
Elastic N.V.
Ordinary Shares |
683.250 | ||||||||
2018-10-04 | 3 | ESTC |
Elastic N.V.
Ordinary Shares |
1.324.908 | ||||||||
2018-10-04 | 3 | ESTC |
Elastic N.V.
Ordinary Shares |
683.250 | ||||||||
2018-09-10 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 12.000.000 | 12.000.000 | 1,67 | 20.000.400 | 20.000.400 | ||
2018-09-10 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 3.000.000 | 82.978.668 | 3,75 | 1,67 | 5.000.100 | 138.300.546 | |
2018-08-22 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 663.716 | 18.698.038 | 3,68 | 2,26 | 1.499.998 | 42.257.566 | |
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Warrant to purchase Common Stock |
J - Other | 40.702 | 40.702 | |||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Warrant to purchase Series D Preferred Stock |
J - Other | -684.911 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series D Preferred Stock |
C - Conversion | -16.502.833 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series C Preferred Stock |
C - Conversion | -3.337.206 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series B Preferred Stock |
C - Conversion | -3.645.307 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
P - Purchase | 545.455 | 2.484.870 | 28,12 | 11,00 | 6.000.005 | 27.333.570 | |
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 980.715 | 1.939.415 | 102,30 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 432.033 | 958.700 | 82,03 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 515.547 | 526.667 | 4.636,21 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 346.239 | 7.729.641 | 4,69 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
8% Convertible Preferred Notes |
C - Conversion | -346.239 | 0 | -100,00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 650.631 | 7.383.402 | 9,66 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series G Convertible Preferred Stock |
C - Conversion | -650.631 | 0 | -100,00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 125.989 | 6.732.771 | 1,91 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series F Convertible Preferred Stock |
C - Conversion | -125.989 | 0 | -100,00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 395.815 | 6.606.782 | 6,37 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series E Convertible Preferred Stock |
C - Conversion | -395.815 | 0 | -100,00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 620.155 | 6.210.967 | 11,09 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series D Convertible Preferred Stock |
C - Conversion | -620.155 | 0 | -100,00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 1.062.944 | 5.590.812 | 23,48 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series C Convertible Preferred Stock |
C - Conversion | -1.062.944 | 0 | -100,00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class B Common Stock |
C - Conversion | 4.527.868 | 4.527.868 | |||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Series B Convertible Preferred Stock |
C - Conversion | -4.527.868 | 0 | -100,00 | ||||
2018-07-31 |
|
4 | BE |
Bloom Energy Corp
Class A Common Stock |
P - Purchase | 1.333.333 | 1.333.333 | 15,00 | 19.999.995 | 19.999.995 | ||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-20 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 50.600 | 18.034.322 | 0,28 | 2,00 | 101.165 | 36.056.020 | |
2018-07-20 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 200.000 | 17.983.722 | 1,12 | 1,95 | 390.580 | 35.120.411 | |
2018-07-20 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 4.322 | 113.230 | 3,97 | ||||
2018-06-28 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 187.130 | 17.783.722 | 1,06 | 2,10 | 392.692 | 37.319.141 | |
2018-06-28 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 5.295 | 17.596.592 | 0,03 | 2,15 | 11.384 | 37.832.673 | |
2018-06-18 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
A - Award | 40.779 | 209.666 | 24,15 | ||||
2018-05-30 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 275 | 17.591.297 | 0,00 | 2,15 | 591 | 37.821.289 | |
2018-05-30 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
A - Award | 416.667 | 3.082.186 | 15,63 | 4,00 | 1.666.668 | 12.328.744 | |
2018-05-30 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
A - Award | 416.667 | 3.082.186 | 15,63 | 4,00 | 1.666.668 | 12.328.744 | |
2018-05-30 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
A - Award | 416.666 | 3.082.186 | 15,63 | 4,00 | 1.666.664 | 12.328.744 | |
2018-05-21 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 32.200 | 17.591.022 | 0,18 | 2,14 | 69.059 | 37.727.465 | |
2018-05-21 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 20.100 | 17.558.822 | 0,11 | 2,14 | 42.928 | 37.500.376 | |
2018-05-21 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 184.179 | 17.538.722 | 1,06 | 2,13 | 391.436 | 37.275.046 | |
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Warrant to Purchase Common Stock (right to buy) |
X - Other | -298.406 | 0 | -100,00 | ||||
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Warrant to Purchase Common Stock (right to buy) |
X - Other | -216.046 | 0 | -100,00 | ||||
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
S - Sale | -5.533 | 4.995.664 | -0,11 | 17,81 | -98.543 | 88.972.776 | |
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
X - Other | 298.406 | 5.001.197 | 6,35 | 0,33 | 98.474 | 1.650.395 | |
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
S - Sale | -4.006 | 4.702.791 | -0,09 | 17,81 | -71.347 | 83.756.708 | |
2018-05-11 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
X - Other | 216.046 | 4.706.797 | 4,81 | 0,33 | 71.295 | 1.553.243 | |
2018-05-10 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 70.873 | 17.354.543 | 0,41 | 2,13 | 151.250 | 37.036.330 | |
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
C - Conversion | -858.978 | 0 | -100,00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
C - Conversion | -2.576.939 | 0 | -100,00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
C - Conversion | -12.679.970 | 0 | -100,00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
U - Other | -858.978 | 0 | -100,00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
C - Conversion | 858.978 | 858.978 | |||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
U - Other | -2.576.939 | 0 | -100,00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
C - Conversion | 2.576.939 | 2.576.939 | |||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
U - Other | -12.679.970 | 0 | -100,00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
C - Conversion | 12.679.970 | 12.679.970 | |||||
2018-04-30 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 4.322 | 108.908 | 4,13 | ||||
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Series A Preferred Stock |
C - Conversion | -6.995.000 | 0 | -100,00 | ||||
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Common Stock |
P - Purchase | 133.333 | 3.312.877 | 4,19 | 15,00 | 1.999.995 | 49.693.155 | |
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Common Stock |
C - Conversion | 3.179.544 | 3.179.544 | |||||
2018-04-10 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 203.200 | 17.283.670 | 1,19 | 2,46 | 499.994 | 42.528.198 | |
2018-04-10 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 32.100 | 17.080.470 | 0,19 | 2,43 | 78.099 | 41.556.784 | |
2018-04-10 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 685.676 | 17.048.370 | 4,19 | 2,24 | 1.536.943 | 38.213.921 | |
2018-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 6.000.000 | 79.978.672 | 8,11 | 1,92 | 11.500.200 | 153.295.121 | |
2018-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 571.164 | 73.978.672 | 0,78 | 1,90 | 1.087.553 | 140.862.789 | |
2018-03-27 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Warrant to Purchase Common Stock |
P - Purchase | 707.964 | 707.964 | 0,12 | 88.496 | 88.496 | ||
2018-03-27 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 707.964 | 3.466.003 | 25,67 | 2,70 | 1.911.503 | 9.358.208 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 294.090 | 73.407.508 | 0,40 | 1,95 | 572.358 | 142.865.692 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 869.574 | 73.113.418 | 1,20 | 1,90 | 1.655.669 | 139.207.948 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 104.844 | 72.243.844 | 0,15 | 1,81 | 189.820 | 130.797.480 | |
2018-03-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
U - Other | -10.882.574 | 0 | -100,00 | ||||
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 3.159 | 739.516 | 0,43 | 59,82 | 188.957 | 44.234.445 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 12.634 | 9.681.129 | 0,13 | 59,82 | 755.708 | 579.080.604 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 4.311 | 736.357 | 0,59 | 59,76 | 257.643 | 44.007.787 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 400 | 732.046 | 0,05 | 59,15 | 23.658 | 43.297.593 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 7.557 | 731.646 | 1,04 | 58,28 | 440.433 | 42.641.426 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 17.248 | 9.668.495 | 0,18 | 59,76 | 1.030.813 | 577.829.869 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 1.600 | 9.651.247 | 0,02 | 59,15 | 94.634 | 570.832.655 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 30.321 | 9.649.647 | 0,32 | 58,28 | 1.767.153 | 562.395.902 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 4.465 | 724.089 | 0,62 | 57,34 | 256.043 | 41.522.449 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 1.020 | 719.624 | 0,14 | 56,66 | 57.794 | 40.774.184 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 1.600 | 718.604 | 0,22 | 55,01 | 88.015 | 39.529.975 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 6.575 | 717.004 | 0,93 | 54,32 | 357.165 | 38.948.804 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 17.859 | 9.619.326 | 0,19 | 57,34 | 1.024.114 | 551.614.478 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 4.080 | 9.601.467 | 0,04 | 56,66 | 231.174 | 544.022.961 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 6.399 | 9.597.387 | 0,07 | 55,01 | 352.005 | 527.946.500 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 26.304 | 9.590.988 | 0,28 | 54,32 | 1.428.875 | 520.997.814 | |
2018-03-02 |
|
4 | TNTR |
Tintri, Inc.
Note Purchase Agreement (obligation to purchase) |
E - Other | 0 | ||||||
2018-02-27 |
|
4 | ABIO |
ARCA biopharma, Inc.
Common Stock |
S - Sale | -1.460.209 | 0 | -100,00 | 0,50 | -731.273 | ||
2018-02-22 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Series E Preferred Stock |
C - Conversion | -1.818.000 | 0 | -100,00 | ||||
2018-02-22 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
C - Conversion | 1.818.000 | 10.882.574 | 20,06 | 3,30 | 5.999.400 | 35.912.494 | |
2018-02-21 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2.000.000 | 5.490.073 | 57,31 | 6,00 | 12.000.000 | 32.940.438 | |
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -2.724.202 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 390 | 1.167 | 50,19 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 777 | 777 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -13.621 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 13.621 | 13.621 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -27.242 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 27.242 | 27.242 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -2.724.202 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 2.724.202 | 2.724.202 | |||||
2018-02-05 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 3.841 | 104.586 | 3,81 | ||||
2018-01-26 |
|
4 | SYBX |
SYNLOGIC, INC.
Common Stock |
A - Award | 410.000 | 4.228.940 | 10,74 | 9,75 | 3.997.500 | 41.232.165 | |
2018-01-23 | 3 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
50.000.000 | ||||||||
2018-01-23 | 3 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
50.000.000 | ||||||||
2018-01-09 | 3 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value |
8.282.616 | ||||||||
2018-01-09 | 3 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value |
8.282.616 | ||||||||
2017-12-19 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 2.000.000 | 5.554.610 | 56,26 | 5,00 | 10.000.000 | 27.773.050 | |
2017-12-08 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
S - Sale | -32.850 | 0 | -100,00 | 2,59 | -85.200 | ||
2017-12-08 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
S - Sale | -12.100 | 32.850 | -26,92 | 2,61 | -31.628 | 85.867 | |
2017-12-08 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock purchase warrant |
X - Other | -139.645 | 0 | -100,00 | ||||
2017-12-08 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
S - Sale | -94.695 | 44.950 | -67,81 | 2,64 | -249.995 | 118.668 | |
2017-12-08 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
X - Other | 139.645 | 139.645 | 1,79 | 249.992 | 249.992 | ||
2017-12-04 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
J - Other | 48.377 | 48.377 | |||||
2017-12-04 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
J - Other | -652.090 | 0 | -100,00 | ||||
2017-12-04 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
J - Other | 652.090 | 652.090 | |||||
2017-12-04 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
J - Other | -2.534.912 | 0 | -100,00 | ||||
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -569.620 | 2.724.202 | -17,29 | ||||
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
S - Sale | -569.620 | 0 | -100,00 | 19,49 | -11.101.894 | ||
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 569.620 | 569.620 | |||||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -2.820.516 | 3.293.822 | -46,13 | ||||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
S - Sale | -2.820.516 | 0 | -100,00 | 19,49 | -54.971.857 | ||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 2.820.516 | 2.820.516 | |||||
2017-11-20 | 3 | ASNS |
Arsanis, Inc.
Common Stock |
4.000.000 | ||||||||
2017-11-20 | 3 | ASNS |
Arsanis, Inc.
Common Stock |
4.000.000 | ||||||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | 290 | 290 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | 290 | 290 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | -1.000.000 | 2.256.013 | -30,71 | ||||
2017-10-23 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 4.037 | 100.745 | 4,17 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A-1 Junior Preferred Stock |
C - Conversion | -2.927.708 | 0 | -100,00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stoc |
C - Conversion | -1.402.870 | 0 | -100,00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 550.000 | 4.909.956 | 12,61 | 17,00 | 9.350.000 | 83.469.252 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 2.927.708 | 4.359.956 | 204,41 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 1.402.870 | 1.432.248 | 4.775,24 | ||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-08-30 |
|
4 | SYBX |
SYNLOGIC, INC.
Common Stock |
A - Award | 3.394.439 | 3.818.940 | 799,63 | ||||
2017-08-10 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
S - Sale | -281.359 | 0 | -100,00 | 3,98 | -1.120.175 | ||
2017-08-10 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
S - Sale | -281.360 | 281.359 | -50,00 | 3,93 | -1.105.717 | 1.105.713 | |
2017-08-10 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 562.719 | 562.719 | |||||
2017-08-10 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 41.283 | 187.444 | 28,24 | ||||
2017-08-10 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 134.620 | 611.225 | 28,25 | ||||
2017-08-10 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | -3.070.000 | 0 | -100,00 | ||||
2017-08-10 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 3.070.000 | 3.070.000 | |||||
2017-08-10 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | -10.000.000 | 0 | -100,00 | ||||
2017-07-31 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
21.978.020 | ||||||||
2017-07-31 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
21.978.020 | ||||||||
2017-07-20 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 5.072 | 96.708 | 5,53 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series C-1 Preferred Stock |
C - Conversion | -2.216.626 | 0 | -100,00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series B-1 Preferred Stock |
C - Conversion | -18.001.419 | 0 | -100,00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series A-1 Preferred Stock |
C - Conversion | -11.931.173 | 0 | -100,00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
P - Purchase | 1.000.000 | 8.140.138 | 14,01 | 15,00 | 15.000.000 | 122.102.070 | |
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
C - Conversion | 7.140.138 | 7.140.138 | |||||
2017-06-15 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
A - Award | 51.964 | 168.887 | 44,44 | ||||
2017-06-13 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
S - Sale | -281.352 | 0 | -100,00 | 3,04 | -854.100 | ||
2017-06-13 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 281.352 | 281.352 | |||||
2017-06-13 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 20.641 | 146.161 | 16,44 | ||||
2017-06-13 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 67.308 | 476.605 | 16,44 | ||||
2017-06-13 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | -1.535.000 | 0 | -100,00 | ||||
2017-06-13 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 1.535.000 | 1.535.000 | |||||
2017-06-13 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | -5.000.000 | 10.000.000 | -33,33 | ||||
2017-06-05 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
P - Purchase | 7.092.198 | 21.911.183 | 47,86 | 1,41 | 9.999.999 | 30.894.768 | |
2017-05-31 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | 6.114.338 | 6.114.338 | |||||
2017-05-31 |
|
4 | APPN |
APPIAN CORP
Series B Convertible Preferred Stock |
C - Conversion | -6.114.338 | 0 | -100,00 | ||||
2017-04-24 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 5.124 | 91.636 | 5,92 | ||||
2017-03-29 |
|
4 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.000.000 | 16.362.694 | 57,90 | 0,50 | 3.000.000 | 8.181.347 | |
2017-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 12.870.000 | 72.139.000 | 21,71 | 0,70 | 9.009.000 | 50.497.300 | |
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
J - Other | 858.978 | 858.978 | |||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
J - Other | 2.576.939 | 2.576.939 | |||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
J - Other | 12.679.970 | 12.679.970 | |||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series G Preferred Stock |
C - Conversion | -227.125 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series A Preferred Stock |
C - Conversion | -631.853 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series G Preferred Stock |
C - Conversion | -681.377 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series A Preferred Stock |
C - Conversion | -1.895.562 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series G Preferred Stock |
C - Conversion | -605.668 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series F Preferred Stock |
C - Conversion | -2.064.048 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series E Preferred Stock |
C - Conversion | -8.000.038 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series A Preferred Stock |
C - Conversion | -1.689.436 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
J - Other | -858.978 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
C - Conversion | 858.978 | 858.978 | |||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
J - Other | -2.576.939 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
C - Conversion | 2.576.939 | 2.576.939 | |||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
J - Other | -12.679.970 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
C - Conversion | 12.359.190 | 12.679.970 | 3.852,86 | ||||
2017-03-16 | 3 | MULE |
MULESOFT, INC
Common Stock |
641.560 | ||||||||
2017-03-16 | 3 | MULE |
MULESOFT, INC
Common Stock |
641.560 | ||||||||
2017-03-02 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
S - Sale | -75.000 | 0 | -100,00 | 4,19 | -313.905 | ||
2017-03-02 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
S - Sale | -112.386 | 75.000 | -59,98 | 4,21 | -473.516 | 315.998 | |
2017-03-01 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
S - Sale | -93.968 | 187.386 | -33,40 | 4,26 | -399.862 | 797.384 | |
2017-03-01 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 281.354 | 281.354 | |||||
2017-03-01 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 20.641 | 125.520 | 19,68 | ||||
2017-03-01 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 67.307 | 409.297 | 19,68 | ||||
2017-03-01 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | -1.535.000 | 0 | -100,00 | ||||
2017-03-01 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | 1.535.000 | 1.535.000 | |||||
2017-03-01 |
|
4 | GRPN |
Groupon, Inc.
Common Stock |
J - Other | -5.000.000 | 15.000.000 | -25,00 | ||||
2017-02-14 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -1.099.996 | 952.809 | -53,59 | 2,01 | -2.211.432 | 1.915.527 | |
2017-02-14 |
|
5 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -136 | 0 | -100,00 | ||||
2017-02-06 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 5.677 | 86.512 | 7,02 | ||||
2017-02-01 | 3 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
18.129.148 | ||||||||
2017-02-01 | 3 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
18.129.148 | ||||||||
2016-12-19 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
P - Purchase | 500.000 | 5.215.128 | 10,60 | 13,50 | 6.750.000 | 70.404.228 | |
2016-11-29 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 869.565 | 2.758.039 | 46,05 | 5,75 | 4.999.999 | 15.858.724 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series B-2 Preferred Stock |
C - Conversion | -4.362.472 | 0 | -100,00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series B-1 Preferred Stock |
C - Conversion | -4.689.657 | 0 | -100,00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -12.447.605 | 0 | -100,00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Warrants to Purchase Common Stock |
X - Other | -80.658 | 0 | -100,00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 338.462 | 3.490.073 | 10,74 | 13,00 | 4.400.006 | 45.370.949 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 623.210 | 3.151.611 | 24,65 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 669.951 | 2.528.401 | 36,05 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.778.227 | 1.858.450 | 2.216,60 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
S - Sale | -435 | 80.223 | -0,54 | 13,00 | -5.655 | 1.042.899 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
X - Other | 80.658 | 80.658 | 0,07 | 5.646 | 5.646 | ||
2016-10-24 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 3.981 | 80.835 | 5,18 | ||||
2016-10-13 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Warrants to Purchase Common Stock |
P - Purchase | 22.343 | 133.835 | 20,04 | ||||
2016-10-13 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Warrants to Purchase Common Stock |
P - Purchase | 61.157 | 366.332 | 20,04 | ||||
2016-09-30 |
|
4/A | ROKA |
Roka BioScience, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 4.000 | 4.000 | |||||
2016-09-28 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Warrants to Purchase Common Stock |
P - Purchase | 66.895 | 111.492 | 150,00 | ||||
2016-09-28 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Warrants to Purchase Common Stock |
P - Purchase | 183.105 | 305.175 | 150,00 | ||||
2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Warrant to Purchase Common Stock (right to buy) |
P - Purchase | 5.714.286 | 5.714.286 | |||||
2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 4.000 | 4.000 | |||||
2016-09-20 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -7.471 | 2.052.805 | -0,36 | 0,75 | -5.603 | 1.539.604 | |
2016-09-15 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -10.000 | 2.060.276 | -0,48 | 0,74 | -7.400 | 1.524.604 | |
2016-09-15 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 461.538 | 3.554.610 | 14,92 | 13,00 | 5.999.994 | 46.209.930 | |
2016-09-15 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Warrants to Purchase Common Stock |
P - Purchase | 44.597 | 44.597 | |||||
2016-09-15 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Warrants to Purchase Common Stock |
P - Purchase | 122.070 | 122.070 | |||||
2016-08-31 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -50.000 | 2.070.276 | -2,36 | 1,01 | -50.440 | 2.088.494 | |
2016-08-26 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -1.200 | 2.120.276 | -0,06 | 1,21 | -1.452 | 2.565.534 | |
2016-08-15 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
S - Sale | -730.349 | 0 | -100,00 | 5,69 | -4.153.933 | ||
2016-08-12 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 730.349 | 730.349 | |||||
2016-08-12 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 53.596 | 104.879 | 104,51 | ||||
2016-08-12 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 174.770 | 341.990 | 104,52 | ||||
2016-08-12 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -3.986.381 | 0 | -100,00 | ||||
2016-08-12 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 3.986.381 | 3.986.381 | |||||
2016-08-12 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -12.984.956 | 20.000.000 | -39,37 | ||||
2016-08-02 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy) |
P - Purchase | 20.120.724 | 20.120.724 | |||||
2016-08-02 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
P - Purchase | 20.120.724 | 55.418.811 | 57,00 | 0,10 | 2.000.000 | 5.508.630 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -8.989 | 2.121.476 | -0,42 | 1,33 | -11.957 | 2.821.987 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -14.158 | 2.130.465 | -0,66 | 1,24 | -17.550 | 2.640.924 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -534 | 2.144.623 | -0,02 | 1,17 | -625 | 2.509.209 | |
2016-07-21 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 5.273 | 76.854 | 7,37 | ||||
2016-07-20 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 763.650 | 2.665.519 | 40,15 | 8,73 | 6.666.664 | 23.269.981 | |
2016-07-20 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 763.650 | 2.665.519 | 40,15 | 8,73 | 6.666.664 | 23.269.981 | |
2016-07-20 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 763.651 | 2.665.520 | 40,15 | 8,73 | 6.666.673 | 23.269.990 | |
2016-07-15 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -13.382 | 2.145.157 | -0,62 | 1,20 | -16.060 | 2.574.403 | |
2016-06-14 |
|
4 | OPWR |
OPOWER, INC.
Common Stock |
U - Other | -8.989.766 | 0 | -100,00 | 10,30 | -92.594.590 | ||
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
S - Sale | -358.382 | 0 | -100,00 | 3,20 | -1.145.353 | ||
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
S - Sale | -281.663 | 358.382 | -44,01 | 3,26 | -918.362 | 1.168.505 | |
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
A - Award | 45.991 | 116.923 | 64,84 | ||||
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 618.665 | 640.045 | 2.893,66 | ||||
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 45.401 | 51.283 | 771,86 | ||||
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 148.044 | 167.220 | 772,03 | ||||
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -3.377.000 | 0 | -100,00 | ||||
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 3.377.000 | 3.377.000 | |||||
2016-06-10 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -11.000.000 | 32.984.956 | -25,01 | ||||
2016-06-07 | 3 | AKAO |
Achaogen Inc
Common Stock |
9.430.256 | ||||||||
2016-06-07 | 3 | AKAO |
Achaogen Inc
Common Stock |
9.430.256 | ||||||||
2016-05-17 | 3 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
20.725.388 | ||||||||
2016-05-17 | 3 | AVEO |
AVEO PHARMACEUTICALS INC
Common Stock |
20.725.388 | ||||||||
2016-04-25 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 4.401 | 71.581 | 6,55 | ||||
2016-03-23 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
P - Purchase | 1.052.631 | 8.949.292 | 13,33 | 2,85 | 2.999.998 | 25.505.482 | |
2016-03-23 |
|
4 | SENS |
Senseonics Holdings, Inc.
Common Stock |
P - Purchase | 1.578.947 | 14.818.985 | 11,93 | 2,85 | 4.499.999 | 42.234.107 | |
2016-03-18 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 710.429 | 710.429 | 35,19 | 24.999.997 | 24.999.997 | ||
2016-03-18 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 710.429 | 710.429 | 35,19 | 24.999.997 | 24.999.997 | ||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
36.939.440 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
31.596.063 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
26.234.314 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
23.727.193 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
36.939.440 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
31.596.063 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
26.234.314 | ||||||||
2016-03-17 | 3 | SENS |
Senseonics Holdings, Inc.
Common Stock |
23.727.193 | ||||||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Series B Convertible Redeemable Preferred Stock |
C - Conversion | -4.423.723 | 0 | -100,00 | ||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Series A Convertible Redeemable Preferred Stock |
C - Conversion | -13.848.000 | 0 | -100,00 | ||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 900.324 | 3.093.072 | 41,06 | 8,00 | 7.202.592 | 24.744.576 | |
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
C - Conversion | 2.192.748 | 2.192.748 | |||||
2016-02-04 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
D - Sale to Issuer | -3.943.269 | 0 | -100,00 | ||||
2016-01-26 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 7.541 | 67.180 | 12,64 | ||||
2016-01-14 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 500.000 | 1.901.869 | 35,67 | 10,00 | 5.000.000 | 19.018.690 | |
2016-01-14 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 500.000 | 1.901.869 | 35,67 | 10,00 | 5.000.000 | 19.018.690 | |
2016-01-14 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 500.000 | 1.902.449 | 35,65 | 10,00 | 5.000.000 | 19.024.490 | |
2016-01-12 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 1.111.111 | 5.854.351 | 23,43 | 9,00 | 9.999.999 | 52.689.159 | |
2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
118.538.000 | ||||||||
2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
118.538.000 | ||||||||
2015-11-18 |
|
4 | GLYC |
GLYCOMIMETICS INC
Warrant to Purchase Common Stock (right to buy) |
X - Other | -9.445 | 0 | -100,00 | 0,33 | -3.117 | ||
2015-11-18 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
S - Sale | -452 | 4.490.751 | -0,01 | 6,91 | -3.123 | 31.031.089 | |
2015-11-18 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
X - Other | 9.445 | 4.491.203 | 0,21 | 0,33 | 3.117 | 1.482.097 | |
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series D-3 Preferred Stock |
C - Conversion | -7.353.023 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series C-3 Preferred Stock |
C - Conversion | -1.248.028 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series B-3 Preferred Stock |
C - Conversion | -5.779.879 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series A-3 Preferred Stock |
C - Conversion | -5.285.557 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series E-3 Preferred Stock |
C - Conversion | -16.217.943 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series D-3 Preferred Stock |
C - Conversion | -26.678.422 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series C-3 Preferred Stock |
C - Conversion | -4.722.375 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series B-3 Preferred Stock |
C - Conversion | -2.889.939 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Series A-3 Preferred Stock |
C - Conversion | -2.522.387 | 0 | -100,00 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Common Stock |
P - Purchase | 214.065 | 971.733 | 28,25 | 5,00 | 1.070.325 | 4.858.665 | |
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Common Stock |
C - Conversion | 756.406 | 757.668 | 59.937,08 | ||||
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Common Stock |
P - Purchase | 585.935 | 2.659.804 | 28,25 | 5,00 | 2.929.675 | 13.299.020 | |
2015-11-18 |
|
4 | XCOM |
XTERA COMMUNICATIONS, INC.
Common Stock |
C - Conversion | 2.040.813 | 2.073.869 | 6.173,81 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 212.650 | 212.650 | |||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 19.040 | 33.996 | 127,31 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 76.192 | 136.041 | 127,31 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -1.172.932 | 0 | -100,00 | ||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 1.172.932 | 1.172.932 | |||||
2015-11-12 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -3.820.625 | 3.820.625 | -50,00 | ||||
2015-11-12 | 3 | XCOM |
XTERA COMMUNICATIONS, INC.
Common Stock |
67.374 | ||||||||
2015-11-12 | 3 | XCOM |
XTERA COMMUNICATIONS, INC.
Common Stock |
35.580 | ||||||||
2015-11-12 | 3 | XCOM |
XTERA COMMUNICATIONS, INC.
Common Stock |
67.374 | ||||||||
2015-11-12 | 3 | XCOM |
XTERA COMMUNICATIONS, INC.
Common Stock |
35.580 | ||||||||
2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Series B Convertible Preferred Stock |
C - Conversion | -16.638.880 | 0 | -100,00 | ||||
2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Common Stock |
C - Conversion | 594.245 | 594.245 | |||||
2015-10-19 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 5.416 | 59.639 | 9,99 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
P - Purchase | 857.142 | 2.971.517 | 40,54 | 7,00 | 5.999.994 | 20.800.619 | |
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
J - Other | 31.650 | 2.114.375 | 1,52 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
J - Other | 257.516 | 1.499.166 | 20,74 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -583.559 | 0 | -100,00 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.241.650 | 0 | -100,00 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
C - Conversion | 583.559 | 2.082.725 | 38,93 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
C - Conversion | 1.241.650 | 1.241.650 | |||||
2015-07-17 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 3.997 | 54.223 | 7,96 | ||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | 1.171 | 1.171 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | 97 | 97 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | 386 | 386 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | 1.134 | 1.134 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | -8.250 | 0 | -100,00 | ||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | 8.250 | 8.250 | |||||
2015-07-02 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
J - Other | -825.000 | 1.786.564 | -31,59 | ||||
2015-06-22 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
A - Award | 28.889 | 70.932 | 68,71 | ||||
2015-06-19 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -48.796 | 0 | -100,00 | 16,02 | -781.800 | ||
2015-06-19 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | 63.085 | 48.796 | -441,49 | 16,67 | 1.051.804 | 813.566 | |
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -55.105 | 111.881 | -33,00 | 16,85 | -928.668 | 1.885.497 | |
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 166.986 | 166.986 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 14.956 | 14.956 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 59.849 | 59.849 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -921.000 | 0 | -100,00 | ||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | 921.000 | 921.000 | |||||
2015-06-17 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
J - Other | -3.000.000 | 7.641.250 | -28,19 | ||||
2015-06-17 | 3 | ABIO |
ARCA biopharma, Inc.
Common Stock |
20.442.930 | ||||||||
2015-06-17 | 3 | ABIO |
ARCA biopharma, Inc.
Common Stock |
20.442.930 | ||||||||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock Warrant (right to buy) |
P - Purchase | 420.561 | 420.561 | 0,12 | 52.570 | 52.570 | ||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock Warrant (right to buy) |
P - Purchase | 420.561 | 420.561 | 0,12 | 52.570 | 52.570 | ||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock Warrant (right to buy) |
P - Purchase | 560.748 | 560.748 | 0,12 | 70.094 | 70.094 | ||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 1.401.869 | 1.401.869 | 10,70 | 14.999.998 | 14.999.998 | ||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 1.401.869 | 1.401.869 | 10,70 | 14.999.998 | 14.999.998 | ||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 1.869.159 | 7.488.893 | 33,26 | 10,70 | 20.000.001 | 80.131.155 | |
2015-06-04 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
S - Sale | -629 | 0 | -100,00 | 58,13 | -36.564 | ||
2015-06-04 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
S - Sale | -1.500 | 629 | -70,46 | 57,55 | -86.332 | 36.202 | |
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 2.129 | 2.129 | |||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 290 | 767 | 60,80 | ||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 290 | 767 | 60,80 | ||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -1.000.000 | 8.854.255 | -10,15 | ||||
2015-05-12 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 3.014 | 50.226 | 6,38 | ||||
2015-05-11 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
U - Other | -68 | 0 | -100,00 | 46,00 | -3.128 | ||
2015-05-11 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
U - Other | -222 | 0 | -100,00 | 46,00 | -10.212 | ||
2015-05-11 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
U - Other | -2.384.221 | 0 | -100,00 | 46,00 | -109.674.166 | ||
2015-03-24 | 3 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Common Stock |
37.500.000 | ||||||||
2015-03-24 | 3 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Common Stock |
37.500.000 | ||||||||
2015-02-17 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 2.680 | 47.212 | 6,02 | ||||
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Series B Redeemable Convertible Preferred Stock |
C - Conversion | -5.373.396 | 0 | -100,00 | ||||
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 500.000 | 1.888.474 | 36,01 | 10,00 | 5.000.000 | 18.884.740 | |
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.388.474 | 1.388.474 | |||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 9/9/2013 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 12/2/2014 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 2/26/14 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
P - Purchase | 23.457 | 2.158.539 | 1,10 | 11,00 | 258.027 | 23.743.929 | |
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
C - Conversion | 341.201 | 2.135.082 | 19,02 | 9,35 | 3.190.229 | 19.963.017 | |
2015-01-29 |
|
4 | BOX |
BOX INC
Class B Common Stock |
J - Other | 2.091.457 | 2.091.457 | |||||
2015-01-29 |
|
4 | BOX |
BOX INC
Series E Preferred Stock |
C - Conversion | -274.916 | 0 | -100,00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Series D2 Preferred Stock |
C - Conversion | -1.653.761 | 0 | -100,00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Existing Class A Common Stock |
J - Other | -2.091.457 | 0 | -100,00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Existing Class A Common Stock |
C - Conversion | 1.928.677 | 2.091.457 | 1.184,84 | ||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-22 | 3 | BOX |
BOX INC
Existing Class A Common Stock |
325.560 | ||||||||
2015-01-22 | 3 | BOX |
BOX INC
Existing Class A Common Stock |
325.560 | ||||||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
S - Sale | -1.972 | 0 | -100,00 | 21,28 | -41.961 | ||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 1.972 | 1.972 | |||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 136 | 136 | |||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 444 | 444 | |||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2014-12-29 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy) |
P - Purchase | 19.868.965 | 19.868.965 | |||||
2014-12-29 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
P - Purchase | 19.868.965 | 35.298.087 | 128,78 | 0,10 | 1.992.857 | 3.540.398 | |
2014-12-22 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -55.994 | 3.569.210 | -1,54 | 8,01 | -448.512 | 28.589.372 | |
2014-12-22 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -27.790 | 3.625.204 | -0,76 | 7,91 | -219.683 | 28.657.600 | |
2014-12-18 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -52.998 | 3.652.994 | -1,43 | 7,90 | -418.742 | 28.862.671 | |
2014-12-18 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -63.094 | 3.705.992 | -1,67 | 7,72 | -487.269 | 28.621.006 | |
2014-12-18 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -27.233 | 3.769.086 | -0,72 | 7,76 | -211.238 | 29.235.669 | |
2014-12-16 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -1.000.000 | 5.619.734 | -15,11 | ||||
2014-12-15 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -16.859 | 3.796.319 | -0,44 | 7,82 | -131.827 | 29.684.937 | |
2014-12-15 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -56.420 | 3.813.178 | -1,46 | 7,93 | -447.174 | 30.222.486 | |
2014-12-15 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -53.182 | 3.869.598 | -1,36 | 7,92 | -421.201 | 30.647.216 | |
2014-12-10 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -31.220 | 3.922.780 | -0,79 | 7,87 | -245.804 | 30.885.224 | |
2014-12-10 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -26.992 | 3.954.000 | -0,68 | 7,79 | -210.195 | 30.790.984 | |
2014-12-10 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -21.448 | 3.980.992 | -0,54 | 7,71 | -165.340 | 30.689.069 | |
2014-12-10 |
|
4 | TRVN |
TREVENA INC
Common Stock |
P - Purchase | 1.000.000 | 4.811.691 | 26,24 | 4,00 | 4.000.000 | 19.246.764 | |
2014-12-08 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 21.380 | 21.380 | |||||
2014-12-08 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 1.389 | 5.882 | 30,91 | ||||
2014-12-08 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 4.528 | 19.176 | 30,91 | ||||
2014-12-08 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -102.000 | 0 | -100,00 | ||||
2014-12-08 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 102.000 | 102.000 | |||||
2014-12-08 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -10.200.000 | 43.984.956 | -18,82 | ||||
2014-12-05 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -18.959 | 4.002.440 | -0,47 | 7,83 | -148.525 | 31.355.115 | |
2014-12-05 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -38.061 | 4.021.399 | -0,94 | 7,83 | -297.903 | 31.475.490 | |
2014-12-05 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -46.635 | 4.059.460 | -1,14 | 7,92 | -369.405 | 32.155.795 | |
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -1.250.000 | 1.964.192 | -38,89 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 69.572 | 69.572 | |||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 6.232 | 14.244 | 77,78 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 24.940 | 57.005 | 77,78 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -383.750 | 0 | -100,00 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 383.750 | 383.750 | |||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -1.250.000 | 0 | -100,00 | ||||
2014-12-04 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 1.250.000 | 1.250.000 | |||||
2014-12-02 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -61.569 | 4.106.095 | -1,48 | 7,90 | -486.432 | 32.440.614 | |
2014-12-02 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -24.796 | 4.167.664 | -0,59 | 7,89 | -195.519 | 32.862.447 | |
2014-12-02 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -50.500 | 4.192.460 | -1,19 | 7,99 | -403.515 | 33.499.432 | |
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 2.639 | 2.639 | |||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 290 | 580 | 100,00 | ||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 290 | 580 | 100,00 | ||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -1.000.000 | 3.994.106 | -20,02 | ||||
2014-11-26 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -76.600 | 4.242.960 | -1,77 | 8,01 | -613.221 | 33.967.016 | |
2014-11-26 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -50.000 | 4.319.560 | -1,14 | 7,90 | -394.990 | 34.123.660 | |
2014-11-26 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -23.400 | 4.369.560 | -0,53 | 7,72 | -180.566 | 33.717.710 | |
2014-11-21 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -24.459 | 4.392.960 | -0,55 | 7,66 | -187.395 | 33.657.102 | |
2014-11-21 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -21.550 | 4.417.419 | -0,49 | 7,69 | -165.655 | 33.956.700 | |
2014-11-21 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -28.991 | 4.438.969 | -0,65 | 7,69 | -223.063 | 34.154.315 | |
2014-10-27 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 4.241 | 44.532 | 10,53 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series C Preferred Stock |
C - Conversion | -382.840 | 0 | -100,00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series B Preferred Stock |
C - Conversion | -655.321 | 0 | -100,00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series A Preferred Stock |
C - Conversion | -2.378.408 | 0 | -100,00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Common Stock |
P - Purchase | 69.112 | 3.502.922 | 2,01 | 16,00 | 1.105.792 | 56.046.752 | |
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Common Stock |
C - Conversion | 3.416.569 | 3.433.810 | 19.816,54 | ||||
2014-10-02 | 3 | DERM |
Dermira, Inc.
Common Stock |
34.482 | ||||||||
2014-10-02 | 3 | DERM |
Dermira, Inc.
Common Stock |
34.482 | ||||||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Series C Preferred Stock |
C - Conversion | -58.692 | 0 | -100,00 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Series B Preferred Stock |
C - Conversion | -1.479.058 | 0 | -100,00 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Series A-2 Preferred Stock |
C - Conversion | -172.825 | 0 | -100,00 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
P - Purchase | 813.474 | 2.611.564 | 45,24 | 8,00 | 6.507.792 | 20.892.512 | |
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
C - Conversion | 58.692 | 1.798.090 | 3,37 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
C - Conversion | 1.479.058 | 1.739.398 | 568,13 | ||||
2014-10-01 |
|
4 | VTAE |
Vitae Pharmaceuticals, Inc
Common Stock |
C - Conversion | 260.340 | 260.340 | |||||
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -11.600 | 4.659.333 | -0,25 | 7,51 | -87.070 | 34.972.953 | |
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -146.800 | 4.670.933 | -3,05 | 7,87 | -1.154.846 | 36.745.296 | |
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -108.300 | 4.817.733 | -2,20 | 8,17 | -884.811 | 39.360.879 | |
2014-08-26 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -7.099 | 0 | -100,00 | 60,40 | -428.773 | ||
2014-08-25 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -27.921 | 7.099 | -79,73 | 61,02 | -1.703.739 | 433.181 | |
2014-08-25 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -24.391 | 35.020 | -41,05 | 60,46 | -1.474.680 | 2.117.309 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -9.348 | 59.411 | -13,60 | 59,79 | -558.917 | 3.552.184 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20.652 | 68.759 | -23,10 | 59,19 | -1.222.392 | 4.069.845 | |
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -1.607.096 | 3.214.192 | -33,33 | ||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 89.411 | 89.411 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 8.012 | 8.012 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 32.065 | 32.065 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -493.378 | 0 | -100,00 | ||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 493.378 | 493.378 | |||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -1.607.096 | 0 | -100,00 | ||||
2014-08-22 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 1.607.096 | 1.607.096 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
S - Sale | -384 | 0 | -100,00 | 36,94 | -14.185 | ||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
S - Sale | -3.027 | 384 | -88,74 | 36,45 | -110.334 | 13.997 | |
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 3.411 | 3.411 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 374 | 374 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 374 | 406.874 | 0,09 | ||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | -12.900 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 12.900 | 12.900 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | -1.290.000 | 4.743.240 | -21,38 | ||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -2.641 | 0 | -100,00 | 26,19 | -69.174 | ||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 2.641 | 2.641 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 290 | 290 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 290 | 290 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -1.000.000 | 4.994.106 | -16,68 | ||||
2014-08-12 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -35.540 | 4.926.033 | -0,72 | 6,76 | -240.190 | 33.291.609 | |
2014-08-12 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -675.000 | 4.961.573 | -11,98 | 6,62 | -4.468.568 | 32.846.109 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.558.651 | 0 | -100,00 | ||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 230.769 | 1.789.420 | 14,81 | 13,00 | 2.999.997 | 23.262.460 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 1.558.651 | 1.558.651 | |||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series E Preferred Stock |
C - Conversion | -5.987.892 | 0 | -100,00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series D Preferred Stock |
C - Conversion | -8.555.784 | 0 | -100,00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series C Preferred Stock |
C - Conversion | -4.030.224 | 0 | -100,00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series B Preferred Stock |
C - Conversion | -12.360.000 | 0 | -100,00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
P - Purchase | 383.333 | 3.216.810 | 13,53 | 12,00 | 4.599.996 | 38.601.720 | |
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 542.381 | 2.833.477 | 23,67 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 801.741 | 2.291.096 | 53,83 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 365.056 | 1.489.355 | 32,47 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 1.119.565 | 1.124.299 | 23.649,45 | ||||
2014-07-17 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 4.169 | 40.291 | 11,54 | ||||
2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock |
9.468 | ||||||||
2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock |
9.468 | ||||||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -72.190 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
J - Other | -468 | 72.190 | -0,64 | 14,00 | -6.552 | 1.010.660 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
X - Other | 72.658 | 72.658 | |||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock Purchase Warrant |
X - Other | -72.658 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -216.573 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
J - Other | -1.402 | 216.573 | -0,64 | 14,00 | -19.628 | 3.032.022 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
X - Other | 217.975 | 217.975 | |||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock Purchase Warrant |
X - Other | -217.975 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -4.404.887 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series A Preferred Stock |
C - Conversion | -1.415.642 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 510.442 | 6.619.734 | 8,36 | 14,00 | 7.146.188 | 92.676.276 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 72.190 | 6.109.292 | 1,20 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 216.573 | 6.037.102 | 3,72 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 4.404.887 | 5.820.529 | 311,16 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 1.415.642 | 1.415.642 | |||||
2014-06-09 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
S - Sale | -1.134 | 0 | -100,00 | 26,90 | -30.506 | ||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 1.134 | 1.134 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 68 | 68 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 222 | 222 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -5.000 | 0 | -100,00 | ||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 5.000 | 5.000 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -500.000 | 2.384.221 | -17,34 | ||||
2014-05-21 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
A - Award | 17.588 | 42.043 | 71,92 | ||||
2014-05-01 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Unit Award (Right to Receive) |
A - Award | 3.750 | 36.122 | 11,58 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Common Stock (right to buy) |
C - Conversion | 55.831 | 55.831 | |||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Series D Preferred Stock (right to buy) |
C - Conversion | -55.831 | 0 | -100,00 | 15,81 | -882.470 | ||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -411.234 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series D Preferred Stock |
C - Conversion | -1.236.487 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series C Preferred Stock |
C - Conversion | -531.758 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series B Preferred Stock |
C - Conversion | -383.249 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series A Preferred Stock |
C - Conversion | -797.208 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 411.234 | 3.943.269 | 11,64 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 1.236.487 | 3.532.035 | 53,86 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 531.758 | 2.295.548 | 30,15 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 383.249 | 1.763.790 | 27,76 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 797.208 | 1.380.541 | 136,66 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 583.333 | 583.333 | 12,00 | 6.999.996 | 6.999.996 | ||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Series C Preferred Stock |
C - Conversion | -1.123.596 | 0 | -100,00 | ||||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Series B Preferred Stock |
C - Conversion | -7.866.170 | 0 | -100,00 | ||||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Common Stock |
C - Conversion | 8.989.766 | 8.989.766 | |||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Series E Preferred Stock |
C - Conversion | -1.065.143 | 0 | -100,00 | ||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Series D Preferred Stock |
C - Conversion | -3.588.446 | 0 | -100,00 | ||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
C - Conversion | 4.653.589 | 4.673.589 | 23.267,94 | ||||
2014-03-27 | 3 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
40.000 | ||||||||
2014-03-27 | 3 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
40.000 | ||||||||
2014-03-13 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -14.500 | 0 | -100,00 | 95,34 | -1.382.475 | ||
2014-03-13 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20.500 | 14.500 | -58,57 | 94,28 | -1.932.767 | 1.367.079 | |
2014-03-13 |
|
4/A | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20 | 0 | -100,00 | 92,49 | -1.850 | ||
2014-03-13 |
|
4/A | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -1.248 | 20 | -98,42 | 91,68 | -114.417 | 1.834 | |
2014-03-13 |
|
4/A | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -22.766 | 1.268 | -94,72 | 90,80 | -2.067.153 | 115.134 | |
2014-03-13 |
|
4/A | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -80 | 0 | -100,00 | 92,49 | -7.399 | ||
2014-03-13 |
|
4/A | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -4.994 | 80 | -98,42 | 91,68 | -457.850 | 7.334 | |
2014-03-13 |
|
4/A | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -91.119 | 5.074 | -94,73 | 90,80 | -8.273.605 | 460.719 | |
2014-03-11 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -24.034 | 0 | -100,00 | 90,84 | -2.183.347 | ||
2014-03-11 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -96.193 | 0 | -100,00 | 90,84 | -8.738.567 | ||
2014-03-11 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -1.491 | 35.000 | -4,09 | 93,07 | -138.765 | 3.257.387 | |
2014-03-11 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -11.433 | 36.491 | -23,86 | 91,05 | -1.041.007 | 3.322.608 | |
2014-03-11 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -10.700 | 47.924 | -18,25 | 90,62 | -969.620 | 4.342.811 | |
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -7.702 | 58.624 | -11,61 | 96,13 | -740.368 | 5.635.332 | |
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -22.146 | 66.326 | -25,03 | 95,42 | -2.113.081 | 6.328.555 | |
2014-03-07 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20.152 | 88.472 | -18,55 | 94,32 | -1.900.672 | 8.344.396 | |
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -1.607.096 | 4.821.288 | -25,00 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 89.428 | 108.624 | 465,87 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -10.804 | 19.196 | -36,01 | 97,31 | -1.051.373 | 1.868.026 | |
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 8.012 | 24.034 | 50,01 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 32.065 | 96.193 | 50,00 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -493.378 | 0 | -100,00 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 493.378 | 493.378 | |||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -1.607.096 | 0 | -100,00 | ||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 1.607.096 | 1.607.096 | |||||
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -10.000 | 30.000 | -25,00 | 96,00 | -960.012 | 2.880.036 | |
2014-03-05 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -20.000 | 40.000 | -33,33 | 95,14 | -1.902.702 | 3.805.404 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -6.516 | 60.000 | -9,80 | 97,11 | -632.769 | 5.826.600 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -14.874 | 66.516 | -18,27 | 96,70 | -1.438.316 | 6.432.097 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -16.547 | 81.390 | -16,90 | 95,54 | -1.580.900 | 7.776.001 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -80.819 | 97.937 | -45,21 | 94,47 | -7.634.971 | 9.252.108 | |
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -3.214.192 | 6.428.384 | -33,33 | ||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 178.756 | 178.756 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 16.022 | 16.022 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 64.128 | 64.128 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -986.757 | 0 | -100,00 | ||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | 986.757 | 986.757 | |||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
J - Other | -3.214.192 | 0 | -100,00 | ||||
2014-02-28 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 3.214.192 | 3.214.192 | |||||
2014-02-12 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | -2.524 | 32.372 | -7,23 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series C Preferred Stock |
C - Conversion | -4.840.686 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
C - Conversion | -1.462.857 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
S - Sale | -487.143 | 1.462.857 | -24,98 | 1,13 | -549.984 | 1.651.566 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
X - Other | 550.000 | 1.950.000 | 39,29 | 1,00 | 550.000 | 1.950.000 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Warrants |
X - Other | -550.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B Preferred Stock |
C - Conversion | -8.400.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series A Preferred Stock |
C - Conversion | -6.000.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
P - Purchase | 472.410 | 3.811.691 | 14,15 | 7,00 | 3.306.870 | 26.681.837 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
C - Conversion | 3.339.281 | 3.339.281 | |||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series E Convertible Preferred Stock |
C - Conversion | -612.089 | 0 | -100,00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series D Convertible Preferred Stock |
C - Conversion | -401.837 | 0 | -100,00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series C Convertible Preferred Stock |
C - Conversion | -2.242.087 | 0 | -100,00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 612.089 | 3.256.013 | 23,15 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 401.837 | 2.643.924 | 17,92 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 2.242 | 2.242.087 | 0,10 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -56.983 | 0 | -100,00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -160.672 | 0 | -100,00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -749.721 | 0 | -100,00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -13.551 | 2.316.692 | -0,58 | 10,96 | -148.519 | 25.390.944 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 56.983 | 2.330.243 | 2,51 | 10,96 | 624.534 | 25.539.463 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -38.210 | 2.273.260 | -1,65 | 10,96 | -418.782 | 24.914.930 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 160.672 | 2.311.470 | 7,47 | 10,96 | 1.760.965 | 25.333.711 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -260.280 | 2.150.798 | -10,80 | 16,00 | -4.164.480 | 34.412.768 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 749.721 | 2.411.078 | 45,13 | 16,00 | 11.995.536 | 38.577.248 | |
2014-01-23 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -169.887 | 5.994.106 | -2,76 | 35,50 | -6.030.988 | 212.790.763 | |
2014-01-21 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -1.132.589 | 6.163.993 | -15,52 | 35,50 | -40.206.910 | 218.821.752 | |
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Series A-1 Preferred Stock |
C - Conversion | -11.824.058 | 0 | -100,00 | ||||
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Series A-1 Preferred Stock |
C - Conversion | -11.250.850 | 0 | -100,00 | ||||
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 512.500 | 4.093.377 | 14,31 | 8,00 | 4.100.000 | 32.747.016 | |
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
C - Conversion | 3.580.877 | 3.580.877 | |||||
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 487.500 | 4.481.758 | 12,21 | 8,00 | 3.900.000 | 35.854.064 | |
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
C - Conversion | 3.407.283 | 3.994.258 | 580,48 | ||||
2014-01-09 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock |
586.975 | ||||||||
2013-12-16 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | -2.563 | 29.848 | -7,91 | ||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -1.452 | 0 | -100,00 | 6,22 | -9.031 | ||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 117 | 230 | 103,54 | ||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 467 | 918 | 103,55 | ||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 1.452 | 1.452 | |||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2013-12-12 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | -1.000.000 | 4.467.960 | -18,29 | ||||
2013-12-05 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
S - Sale | -1.000 | 0 | -100,00 | 5,13 | -5.131 | ||
2013-11-22 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
S - Sale | -5.333 | 1.000 | -84,21 | 5,16 | -27.533 | 5.163 | |
2013-11-20 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -1.152.625 | 9.642.576 | -10,68 | ||||
2013-11-20 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -1.152.625 | 0 | -100,00 | 62,72 | -72.298.403 | ||
2013-11-20 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 1.152.625 | 1.152.625 | |||||
2013-11-19 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
S - Sale | -41.260 | 0 | -100,00 | 10,51 | -433.824 | ||
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 25.800 | 406.500 | 6,78 | 19,31 | 498.185 | 7.849.312 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 23.700 | 380.700 | 6,64 | 20,31 | 481.269 | 7.730.761 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 163.620 | 357.000 | 84,61 | 19,04 | 3.115.538 | 6.797.744 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 152.459 | 193.380 | 372,57 | 19,99 | 3.047.335 | 3.865.260 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 40.921 | 40.921 | 20,91 | 855.654 | 855.654 | ||
2013-11-14 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -6.756.077 | 10.795.201 | -38,49 | ||||
2013-11-14 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -6.756.077 | 0 | -100,00 | 62,72 | -423.774.930 | ||
2013-11-14 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 6.756.077 | 6.756.077 | |||||
2013-11-13 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -201.012 | 1.661.357 | -10,79 | 32,37 | -6.506.758 | 53.778.126 | |
2013-11-13 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -903.229 | 1.862.369 | -32,66 | 32,37 | -29.237.523 | 60.284.885 | |
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
S - Sale | -2.573 | 0 | -100,00 | 9,83 | -25.288 | ||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 2.573 | 2.573 | |||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 233 | 467 | 99,57 | ||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 935 | 1.875 | 99,47 | ||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | -14.390 | 0 | -100,00 | ||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 14.390 | 14.390 | |||||
2013-11-06 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | -1.439.003 | 1.439.002 | -50,00 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 20 | 20 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 42 | 405 | 11,57 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 167 | 1.622 | 11,48 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | -2.847 | 0 | -100,00 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 2.847 | 2.847 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | -284.950 | 284.950 | -50,00 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 3.994 | 3.994 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 363 | 363 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 1.455 | 1.455 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | -22.394 | 0 | -100,00 | ||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | 22.394 | 22.394 | |||||
2013-10-31 |
|
4 | XOOM |
XOOM Corp
Common Stock |
J - Other | -2.239.385 | 2.239.385 | -50,00 | ||||
2013-09-26 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | 2.244 | 27.285 | 8,96 | ||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 41.260 | 41.260 | |||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 2.723 | 4.493 | 153,84 | ||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 8.878 | 14.648 | 153,86 | ||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -200.000 | 0 | -100,00 | ||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 200.000 | 200.000 | |||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -20.000.000 | 54.184.956 | -26,96 | ||||
2013-09-12 |
|
4/A | GRPN |
Groupon, Inc.
Restricted Stock Units |
A - Award | 9.607 | 9.607 | |||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
S - Sale | -1.414 | 0 | -100,00 | 7,16 | -10.121 | ||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 113 | 113 | |||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 451 | 451 | |||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 1.414 | 1.414 | |||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | -9.650 | 0 | -100,00 | ||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | 9.650 | 9.650 | |||||
2013-08-23 |
|
4 | WIFI |
BOINGO WIRELESS INC
Common Stock |
J - Other | -965.000 | 5.467.960 | -15,00 | ||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
S - Sale | -27.595 | 0 | -100,00 | 9,77 | -269.628 | ||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 27.595 | 27.595 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 1.770 | 1.770 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 5.770 | 5.770 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -130.000 | 0 | -100,00 | ||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 130.000 | 130.000 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -13.000.000 | 74.184.956 | -14,91 | ||||
2013-08-14 |
|
4 | CVT |
CVENT INC
Series A Preferred Stock |
C - Conversion | -7.296.582 | 0 | -100,00 | ||||
2013-08-14 |
|
4 | CVT |
CVENT INC
Common Stock |
C - Conversion | 7.296.582 | 7.296.582 | |||||
2013-07-18 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
D - Sale to Issuer | -5.833.213 | 0 | -100,00 | ||||
2013-06-17 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | -3.827 | 25.041 | -13,26 | ||||
2013-06-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
A - Award | 15.306 | 24.455 | 167,30 | ||||
2013-06-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
A - Award | 9.149 | 9.149 | |||||
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Series B Preferred Stock |
C - Conversion | -16.899.721 | 0 | -100,00 | ||||
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 400.000 | 6.033.240 | 7,10 | 15,00 | 6.000.000 | 90.498.600 | |
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
C - Conversion | 5.633.240 | 5.633.240 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
S - Sale | -3.583 | 0 | -100,00 | 39,00 | -139.726 | ||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 3.583 | 3.583 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 477 | 477 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 477 | 477 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -16.450 | 0 | -100,00 | ||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 16.450 | 16.450 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -1.645.000 | 9.854.255 | -14,31 | ||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2.483 | 2.483 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 330 | 330 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 330 | 330 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -11.399 | 0 | -100,00 | ||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 11.399 | 11.399 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -1.139.890 | 2.279.781 | -33,33 | ||||
2013-06-04 |
|
4 | TRGT |
TARGACEPT INC
Stock Option (Right to Buy) |
X - Other | -1.000 | 0 | -100,00 | ||||
2013-06-04 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
X - Other | 1.000 | 6.333 | 18,75 | 0,08 | 75 | 475 | |
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
C - Conversion | -44.249.588 | 0 | -100,00 | ||||
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
S - Sale | -95.980 | 44.249.588 | -0,22 | 0,88 | -83.982 | 38.718.390 | |
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
X - Other | 122.602 | 44.345.568 | 0,28 | 0,68 | 83.982 | 30.376.714 | |
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Warrant to Purchase Series C Preferred Stock (right to buy) |
X - Other | -122.602 | 0 | -100,00 | ||||
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
C - Conversion | 2.765.599 | 2.765.599 | |||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | -2.000.000 | 17.551.278 | -10,23 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | 6.541.485 | 19.551.278 | 50,28 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Series B Preferred Stock |
C - Conversion | -6.541.485 | 0 | -100,00 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class B Common Stock |
C - Conversion | 10.602.127 | 13.009.793 | 440,35 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Series A Preferred Stock |
C - Conversion | -10.602.127 | 0 | -100,00 | ||||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
S - Sale | -2.000.000 | 0 | -100,00 | 28,83 | -57.660.000 | ||
2013-05-23 |
|
4 | DATA |
Tableau Software Inc
Class A Common Stock |
C - Conversion | 2.000.000 | 2.000.000 | |||||
2013-05-23 | 3 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
15.429.122 | ||||||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6.165.747 | 0 | -100,00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Secured Convertible Promissory Note |
C - Conversion | -633.219 | 0 | -100,00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Warrant (right to buy) |
C - Conversion | -156.250 | 0 | -100,00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 625.000 | 5.833.213 | 12,00 | 8,00 | 5.000.000 | 46.665.704 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 4.418.940 | 5.208.213 | 559,87 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 633.219 | 789.273 | 405,77 | 8,00 | 5.065.752 | 6.314.184 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
S - Sale | -196 | 156.054 | -0,13 | 8,00 | -1.568 | 1.248.432 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 156.250 | 156.250 | 0,01 | 1.562 | 1.562 | ||
2013-04-11 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Secured Convertible Promissory Note |
A - Award | 633.219 | 633.219 | |||||
2013-04-11 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Warrant (right to buy) |
A - Award | 156.250 | 156.250 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | -2.321.212 | 4.642.425 | -33,33 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 117 | 117 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 117 | 117 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 316 | 316 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 5.344 | 10.396 | 105,78 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 1.031 | 1.704 | 153,19 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -23.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 23.212 | 23.212 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -2.321.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
C - Conversion | 2.321.212 | 2.321.212 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | -2.321.212 | 4.642.425 | -33,33 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 5.052 | 5.052 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 673 | 673 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 673 | 673 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -23.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 23.212 | 23.212 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -2.321.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
C - Conversion | 2.321.212 | 2.321.212 | |||||
2013-03-08 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
S - Sale | -2.792 | 0 | -100,00 | 12,96 | -36.187 | ||
2013-03-04 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | 5.795 | 21.215 | 37,58 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series F Convertible Preferred Stock |
C - Conversion | -569.900 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series F Convertible Preferred Stock |
C - Conversion | -189.966 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series E Convertible Preferred Stock |
C - Conversion | -681.458 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series D Convertible Preferred Stock |
C - Conversion | -848.420 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series C-1 Convertible Preferred Stock |
C - Conversion | -502.386 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Series C Convertible Preferred Stock |
C - Conversion | -2.256.540 | 0 | -100,00 | ||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Common Stock |
C - Conversion | 569.900 | 569.900 | |||||
2013-02-25 |
|
4 | XOOM |
XOOM Corp
Common Stock |
C - Conversion | 4.478.770 | 4.478.770 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 2.792 | 2.792 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 234 | 234 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 940 | 940 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | -14.000 | 0 | -100,00 | ||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | 14.000 | 14.000 | |||||
2013-02-20 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
J - Other | -1.400.000 | 2.878.005 | -32,73 | ||||
2012-12-03 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | 5.782 | 15.420 | 59,99 | ||||
2012-11-20 |
|
4 | TRGT |
TARGACEPT INC
Stock Option (Right to Buy) |
X - Other | -3.333 | 0 | -100,00 | ||||
2012-11-20 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
X - Other | 3.333 | 5.333 | 166,65 | 0,08 | 250 | 400 | |
2012-10-30 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
S - Sale | -1.597.787 | 8.196.614 | -16,31 | 13,44 | -21.478.252 | 110.182.984 | |
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | 6.963.636 | 13.927.273 | 100,00 | ||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -6.963.636 | 0 | -100,00 | ||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | 6.963.637 | 6.963.637 | |||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -6.963.637 | 0 | -100,00 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -64.634 | 0 | -100,00 | 27,67 | -1.788.494 | ||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -10.352 | 0 | -100,00 | 27,79 | -287.714 | ||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.352 | 10.352 | |||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 2.451 | 8.475 | 40,69 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 614 | 2.128 | 40,55 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -45.000 | 0 | -100,00 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 45.000 | 45.000 | |||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -4.500.000 | 9.038.379 | -33,24 | ||||
2012-08-30 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | 6.090 | 9.638 | 171,68 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-1 Preferred Stock |
C - Conversion | -611.185 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -2.043 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -2.043 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
J - Other | -51.744 | 2.043 | -96,20 | 10,00 | -517.440 | 20.430 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
J - Other | -51.744 | 2.043 | -96,20 | 10,00 | -517.440 | 20.430 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
X - Other | 53.787 | 53.787 | |||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
X - Other | 53.787 | 53.787 | |||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Preferred Stock Warrant (right to buy) |
X - Other | -53.787 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Preferred Stock Warrant (right to buy) |
X - Other | -53.787 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock Warrant (right to buy) |
X - Other | -125.291 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -898.808 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
P - Purchase | 500.000 | 2.884.221 | 20,97 | 10,00 | 5.000.000 | 28.842.210 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 177.481 | 2.384.221 | 8,04 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 180.459 | 2.206.740 | 8,91 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 434.096 | 2.026.281 | 27,26 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 2.043 | 1.592.185 | 0,13 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 2.043 | 1.592.185 | 0,13 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -51.119 | 1.588.099 | -3,12 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
X - Other | 125.291 | 1.639.218 | 8,28 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 898.808 | 1.513.927 | 146,12 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 611.185 | 615.119 | 15.535,97 | ||||
2012-07-25 | 3 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
3.934 | ||||||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Series B Preferred Stock |
C - Conversion | -5.253.859 | 0 | -100,00 | ||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Series A Preferred Stock |
C - Conversion | -5.134.285 | 0 | -100,00 | ||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 1.111.111 | 11.499.255 | 10,70 | 13,50 | 14.999.998 | 155.239.942 | |
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
C - Conversion | 10.388.144 | 10.388.144 | |||||
2012-07-03 |
|
4 | VG |
VONAGE HOLDINGS CORP
Director Stock Option (Right to Buy) |
A - Award | 10.000 | 10.000 | |||||
2012-07-03 |
|
4 | VG |
VONAGE HOLDINGS CORP
Common Stock |
A - Award | 4.975 | 121.640 | 4,26 | ||||
2012-06-21 |
|
4 | GRPN |
Groupon, Inc.
Restricted Stock Units |
A - Award | 9.149 | 9.149 | |||||
2012-05-31 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -2.993 | 0 | -100,00 | 11,65 | -34.868 | ||
2012-05-31 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | 2.993 | 2.993 | |||||
2012-05-31 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | 251 | 419 | 149,40 | ||||
2012-05-31 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | 1.007 | 1.677 | 150,30 | ||||
2012-05-31 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | -15.000 | 0 | -100,00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series E Preferred Stock |
C - Conversion | -1.349.396 | 0 | -100,00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series D Preferred Stock |
C - Conversion | -1.111.435 | 0 | -100,00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series C Preferred Stock |
C - Conversion | -450.952 | 0 | -100,00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series B-1 Preferred Stock |
C - Conversion | -230.379 | 0 | -100,00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Series B Preferred Stock |
C - Conversion | -1.135.843 | 0 | -100,00 | ||||
2012-05-16 |
|
4 | ADNC |
AUDIENCE INC
Common Stock |
C - Conversion | 4.278.005 | 4.278.005 | |||||
2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -24.965.000 | 0 | -100,00 | ||||
2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.400.000 | 10.641.250 | 70,50 | 5,00 | 22.000.000 | 53.206.250 | |
2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 6.241.250 | 6.241.250 | |||||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -16.101 | 0 | -100,00 | 26,53 | -427.211 | ||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 16.101 | 16.101 | |||||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 3.815 | 6.024 | 172,70 | ||||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 956 | 1.514 | 171,33 | ||||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -69.998 | 0 | -100,00 | ||||
2012-04-30 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | 2.202 | 3.548 | 163,67 | ||||
2012-04-30 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
A - Award | 5.302 | 5.302 | |||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Series D Preferred Stock |
C - Conversion | -1.758.302 | 0 | -100,00 | ||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Series C Preferred Stock |
C - Conversion | -8.036.099 | 0 | -100,00 | ||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
C - Conversion | 9.794.401 | 9.794.401 | |||||
2012-04-02 |
|
4 | VG |
VONAGE HOLDINGS CORP
Director Stock Option (Right to Buy) |
A - Award | 10.000 | 10.000 | |||||
2012-04-02 |
|
4 | VG |
VONAGE HOLDINGS CORP
Common Stock |
A - Award | 4.524 | 116.665 | 4,03 | ||||
2012-03-30 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | 5.000 | 15.000 | 50,00 | ||||
2012-03-30 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | -500.000 | 4.529.190 | -9,94 | ||||
2012-03-28 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2012-03-28 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
J - Other | -1.000.000 | 5.029.190 | -16,59 | ||||
2012-03-16 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 69.998 | 16,67 | ||||
2012-03-16 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 13.538.379 | -6,88 | ||||
2012-03-13 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 9.998 | 59.998 | 20,00 | ||||
2012-03-13 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 14.538.379 | -6,44 | ||||
2012-03-09 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 925.154 | 4.584.311 | 25,28 | 5,70 | 5.273.378 | 26.130.573 | |
2012-03-09 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 214.846 | 1.066.029 | 25,24 | 5,70 | 1.224.622 | 6.076.365 | |
2012-03-07 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 50.000 | 25,00 | ||||
2012-03-07 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 15.538.379 | -6,05 | ||||
2012-03-06 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
S - Sale | -2.281 | 0 | -100,00 | 17,98 | -41.019 | ||
2012-03-06 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 1.380 | 2.281 | 153,16 | ||||
2012-03-06 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 327 | 545 | 150,00 | ||||
2012-03-06 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 82 | 137 | 149,09 | ||||
2012-03-06 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | -6.000 | 0 | -100,00 | ||||
2012-03-06 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 6.000 | 6.000 | |||||
2012-03-06 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | -600.000 | 1.420.219 | -29,70 | ||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 901 | 901 | |||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 218 | 218 | |||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 55 | 55 | |||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | -4.000 | 0 | -100,00 | ||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 4.000 | 4.000 | |||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | -400.000 | 2.020.219 | -16,53 | ||||
2012-03-01 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -455.360 | 6.029.190 | -7,02 | 11,42 | -5.199.164 | 68.839.483 | |
2012-02-29 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 40.000 | 33,33 | ||||
2012-02-29 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 16.538.379 | -5,70 | ||||
2012-02-28 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -334.457 | 6.484.550 | -4,90 | 11,40 | -3.812.810 | 73.923.870 | |
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 30.000 | 50,00 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 17.538.379 | -5,39 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 20.000 | 100,00 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 18.538.379 | -5,12 | ||||
2012-02-24 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -54.849 | 6.819.007 | -0,80 | 11,75 | -644.344 | 80.106.967 | |
2012-02-24 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -253.211 | 6.873.856 | -3,55 | 11,68 | -2.957.808 | 80.294.887 | |
2012-02-24 |
|
4 | INWK |
INNERWORKINGS INC
Common Stock |
S - Sale | -2.213 | 0 | -100,00 | 11,60 | -25.671 | ||
2012-02-23 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2012-02-23 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 19.538.379 | -4,87 | ||||
2012-02-17 |
|
4 | GRPN |
Groupon, Inc.
Deferred Stock Units |
A - Award | 1.345 | 1.345 | |||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock Warrant (Right to Buy) |
U - Other | -791.015 | 0 | -100,00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock Warrant (Right to Buy) |
U - Other | -263.671 | 0 | -100,00 | ||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -746.596 | 0 | -100,00 | 26,00 | -19.411.496 | ||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
J - Other | 746.596 | 746.596 | |||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -248.864 | 0 | -100,00 | 26,00 | -6.470.464 | ||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
J - Other | 248.864 | 248.864 | |||||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -6.898.294 | 0 | -100,00 | 26,00 | -179.355.644 | ||
2012-02-15 |
|
4 | INHX |
INHIBITEX, INC.
Common Stock |
U - Other | -1.941.407 | 0 | -100,00 | 26,00 | -50.476.582 | ||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -4.462 | 0 | -100,00 | 22,84 | -101.908 | ||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 2.234 | 4.462 | 100,27 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 550 | 2.209 | 33,15 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 139 | 558 | 33,17 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 20.538.379 | -4,64 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 2.228 | 2.228 | |||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 550 | 1.659 | 49,59 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 139 | 419 | 49,64 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 21.538.379 | -4,44 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -23.083 | 64.634 | -26,32 | 23,05 | -532.063 | 1.489.814 | |
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -4.354 | 0 | -100,00 | 22,63 | -98.517 | ||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 4.354 | 4.354 | |||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 1.109 | 1.109 | |||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 280 | 280 | |||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -20.000 | 0 | -100,00 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 20.000 | 100,00 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 22.538.379 | -4,25 | ||||
2012-01-03 |
|
4 | VG |
VONAGE HOLDINGS CORP
Director Stock Option (Right to Buy) |
A - Award | 10.000 | 10.000 | |||||
2012-01-03 |
|
4 | VG |
VONAGE HOLDINGS CORP
Common Stock |
A - Award | 4.081 | 112.141 | 3,78 |